Skip to content
★ Sign in to follow
Zylox-Tonbridge Medical Technology Co., Ltd. logo

Zylox-Tonbridge Medical Technology Co., Ltd. Stock: price and insider trades · Hong Kong

HK·Mcap HK$6.6BHealth Care

Zylox-Tonbridge Medical Technology Co., Ltd.: what insiders have been doing

Zylox-Tonbridge Medical Technology Co., Ltd., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to HKEX. Between 22 October 2025 and 22 October 2026, 5 insiders published 17 filings.

All open-market trades in the period are sales: 3 sales worth €17.0M, by 3 insiders, with no purchase on record. Biggest ticket of the year: €7.8M, sold by Zhao Jonathon Zhong and made public on 13 April 2026 (1.1% of market cap).

With 17 filings in twelve months, the company is more active than the median of 4 filings across the 1,314 companies we follow on the same exchange. Looking back to 2026, when coverage begins, insiders filed no purchases and 3 sales.

Filings reach the HKEX feed a median of 4 days after the trade. The shorter that gap, the sooner other investors can see what insiders have done. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.

Other companies in the same sector with recent insider buying flagged by our signals: UCB. Source: insider filings from HKEX. Past trades are no guide to future returns.

Insider Decl.
17
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€17M
3 ops. · all time

Who traded when

BuySale
Li Zheng1 sale
Xie Yang1 sale
Zhao Jonathon Zhong1 sale

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 13,673 of 26,911 companies
51.0
score / 100
Value
27
Quality
75
FCF yld-0.3%
Earn yld1.5%
EV/EBITDA47.9x
ROE9.8%
Gross mgn72%
Net mgn13%
Debt/EBITDA0.6x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2024

FY ended December 2024 · cache

HK$20.10
Analyst consensus
5 analysts
1.40/5
HK$29.15Target HK$31.17(+55%)HK$33.23
Income statement
RevenueHK$782.5M
Gross profitHK$559.9M72% margin
EBITDAHK$140.3M18% margin
Net incomeHK$100.3M25.2% margin
Valuation
PER (trailing)18.8x
PER (forward)13.8x
P/Book1.9x
Beta0.33
Balance sheet & cash
Market capHK$6.6B
Total debtHK$90.9M
Free Cash Flow-HK$17.3M
Debt / Equity14%
Profitability & ownership
ROE9.8%
ROA5.1%
% insiders48.1%
% institutions32.2%
Last declaration on 4 May 2026
Declarations17 total
  • ●
    DirectorExecutives
    €144k14HKEX
    6,250 shares0.020% mcap33.9% of flowShareXHKGHKEX:DA20260430E00443
  • ●
    DirectorExecutives
    €2.3M12HKEX
    100,000 shares0.32% mcap5.9% of flowShareXHKGHKEX:DA20260430E00237
  • ●
    DirectorExecutives
    €97k14HKEX
    4,250 shares0.013% mcap31.7% of flowShareXHKGHKEX:DA20260430E00243
  • ●
    DirectorExecutives
    €3.7M12HKEX
    160,000 shares0.51% mcap14.5% of flowShareXHKGHKEX:DA20260430E00222
  • ●
    DirectorExecutives
    €1.1M12HKEX
    50,000 shares0.16% mcap7.6% of flowShareXHKGHKEX:DA20260430E00242
  • ●
    DirectorExecutives
    €1.1M11HKEX
    50,000 shares0.16% mcap4.5% of flowShareXHKGHKEX:DA20260430E00230
  • ●
    DirectorExecutives
    €3.7M12HKEX
    160,000 shares0.51% mcap9.4% of flowShareXHKGHKEX:DA20260430E00234
  • ●
    Executives
    €12.6M10HKEX
    540,000 shares1.74% mcap83.7% of flowShareXHKGHKEX:DA20260420E00400
  • ●
    Executives
    €12.6M7HKEX
    540,000 shares1.74% mcap49.9% of flowShareXHKGHKEX:DA20260420E00393
  • ●
    Executives
    €25.3M8HKEX
    1,080,000 shares3.49% mcap64.7% of flowShareXHKGHKEX:DA20260420E00397
  • ●
    Executives
    €210k9HKEX
    9,000 shares0.029% mcap68.3% of flowShareXHKGHKEX:DA20260420E00387
  • ●
    Executives
    €281k9HKEX
    12,000 shares0.039% mcap66.1% of flowShareXHKGHKEX:DA20260420E00398
  • ▼
    Executives
    12M HKD18HKEX
    569,396 shares@ HK$21.000.18% mcap8.7% of flowShareXHKGHKEX:DA20260410E00507
  • ▼
    Executives
    72M HKD19HKEX
    3,420,000 shares@ HK$21.001.09% mcap20.1% of flowShareXHKGHKEX:DA20260410E00506
  • ▼
    Executives
    72M HKD20HKEX
    3,420,000 shares@ HK$21.001.09% mcap31.0% of flowShareXHKGHKEX:DA20260410E00497
  • ●
    Executives
    0HKEX
    11,476,617 sharesShareXHKGHKEX:DA20260410E00211
  • ●
    Executives
    0HKEX
    11,476,617 sharesShareXHKGHKEX:DA20260410E00220

17 of 17 declarations

About Zylox-Tonbridge Medical Technology Co., Ltd.

Zylox-Tonbridge Medical Technology Co., Ltd. is a company focused on the development and manufacturing of innovative medical technologies. It is listed on the Hong Kong Stock Exchange, XHKG.